Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial

Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized tria...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2004-04, Vol.22 (7), p.1301-1307
Hauptverfasser:	AUERBACH, Michael, BALLARD, Harold, TROUT, J. Richard, MCILWAIN, Marilyn, ACKERMAN, Alan, BAHRAIN, Huzefa, BALAN, Stefan, BARKER, Lance, RANA, Jeevindra
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities, Drug-Induced Administration, Oral Aged Anemia - drug therapy Anemia - etiology Anemias. Hemoglobinopathies Antineoplastic Agents - adverse effects Biological and medical sciences Diseases of red blood cells Erythropoietin - therapeutic use Female Hematologic and hematopoietic diseases Humans Infusions, Intravenous Iron - administration & dosage Iron-Dextran Complex - administration & dosage Male Medical sciences Middle Aged Neoplasms - drug therapy Prospective Studies Quality of Life Recombinant Proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients. This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb
ISSN:	0732-183X 1527-7755
DOI:	10.1200/JCO.2004.08.119